 The FDA has granted Fast Track Designation for Genprex Incs NASDAQ: GNPX lead drug candidate, Reqorsa Immunogene combination therapy. The designation covers Reqorsa combined with Merck Co Incs NYSE: MRK Keytruda for unresectable stage III or IV non-small cell lung cancer NSCLC whose disease progressed after treatment with Keytruda. 